Join to access to all OVN content. Join for Free
How to Start a Diversity Equity & Inclusion Program in Pharma
Provide 5 keywords for SEO search separated by commas

How to Start a Diversity Equity & Inclusion Program in Pharma


Share This Article


Summary

In this episode, Tara Gonzalez joins to discuss the intricacies of establishing Diversity, Equity, and Inclusion (DEI) programs within organizations. She shares insights from her background and outlines the challenges and strategies for initiating DEI initiatives. Tara emphasizes the importance of structuring DEI functions and engaging the entire company, while highlighting the role of external consultants in conducting needs assessments. The conversation covers best practices, the necessity of leadership buy-in, and the ongoing development of DEI efforts. Tara concludes with valuable advice for those looking to implement DEI programs, providing a comprehensive overview of this crucial topic.

This episode features Tara Gonzales, Vice President Medical Affairs discusses how to start a DEI program in Pharma
Tara shares….

👉 How she stood up a DEI program from scratch
👉 Why there is such a need for DEI programs
👉 What companies can expect as far as impact of a well run DEI program
👉 What it takes to build a positive culture in a company

Click for Source
Provide 5 keywords for SEO search separated by commas

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Leveraging Creativity to Break into Your First MSL Role
Partner Avatar MSL Talk: Tom Caravela, Alec McCarthy

Leveraging Creativity to Break into Your First MSL Role

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
OVN Avatar Karen Geary

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Article
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
OVN Avatar J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Explore OVN